Pyrazole derivatives having a pyridazine and pyridine functionality
AssigneeDaiichi Pharmaceutical Co., Ltd.
InventorsNaoaki Kanaya, Hiroaki Ishihara, Youichi Kimura, Takashi Ishiyama, Yuichi Ochiai
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a strong platelet aggregation-inhibiting agent which does not inhibit COX-1 or COX-2. Further, the present invention provides compounds represented by formula (I), salts of the compounds, and solvates or hydrates of the compounds or the salts. Also provided are medicaments containing any of the compounds, salts, or solvates and preventive and/or therapeutic agents for ischemic diseases, containing any of the compounds, salts, or the solvates or hydrates.
Claims12
A compound represented by formula (I), or a salt of the compound:
- wherein Ar1 represents
- a pyridyl group having 1 to 3 substituents wherein the substituents are selected from the group consisting of C1-6 alkyl, halogeno, C1-6 alkoxy, C1-6 alkylamino, and di(C1-6 alkyl)amino groups, or
- a pyridazinyl group having 1 to 3 substituents wherein the substituents are selected from the group consisting of C1-6 alkyl, halogeno, C1-6 alkoxy, C1-6 alkylamino, and di(C1-6 alkyl) amino groups,
- Ar2 represents
- a pyridyl group which may have 1 to 3 substituents wherein the substituents are selected from the group consisting of C1-6 alkyl, halogeno, C1-6 alkoxy, C1-6 alkylamino, and di(C1-6 alkyl)amino groups, or
- a pyridazinyl group which may have 1 to 3 substituents wherein the substituents are selected from the group consisting of C1-6 alkyl, halogeno, C1-6 alkoxy, C1-6 alkylamino, and di(C1-6 alkyl)amino groups,
- wherein is one of Ar1 and Ar2 is pyridazine which may be substituted as defined herein and the other one of Ar1 and Ar2 is pyridine which may be substituted as defined herein,
- R1 is a group represented by formula (1):
- wherein ring structure A represents an azetidine ring, pyrrolidine ring, imidazolidine ring, pyrazolidine ring, piperidine ring, piperazine ring, morpholine ring, thiomorpholine ring, hexahydropyridazine ring, hexahydropyrimidine ring, homopiperazine ring, or oxazepane ring;
- X represents a carbonyl group;
- R3 represents 1 to 4 groups on ring structure A, R3 being selected from the group consisting of a hydrogen atom, a halogeno group, a hydroxyl group, a C1-6 alkoxy group, a C1-6 alkoxycarbonyl group, a carboxyl group, a sulfo group, a C1-6 alkylsulfonyl group, a C1-6 alkyl group which may have 1 or 2 substituents, an amino group which may have 1 or 2 substituents, a carbamoyl group which may have 1 or 2 substituents, a C1-6 acyl group, an aminosulfonyl group which may have 1 or 2 substituents, an oxo group, a hydroxyiminocarbonyl group, a C1-6 alkoxyiminocarbonyl group, and a substituted or non-substituted 3- to 6-membered spiro alicyclic alkyl group;
- and R2 represents a hydrogen atom, a halogeno group, or a C1-6 alkyl group which may have 1 or 2 substituents.
A compound or a salt of the compound, the compound being selected from the group consisting of:
1-[1-(6-Methoxy-3-pyridazinyl)-5-(2-pyridyl)pyrazole-3-carbonyl)-4-methylpiperazine, or a salt of the compound.
Dependencies are inferred from the claim text.